<?xml version="1.0" encoding="UTF-8"?><article>
  <article-id pub-id-type="internal">14640</article-id>
  <article-id pub-id-type="doi">10.30848/PJB2027-3(11)</article-id>
  <article-title>&lt;p&gt;
	LC-MS QTOF analysis of &lt;em&gt;&lt;em&gt;Valeriana wallichii&lt;/em&gt;&lt;/em&gt; DC. and integrated &lt;em&gt;in silico &lt;/em&gt;and &lt;em&gt;in vitro&lt;/em&gt; analysis for potential antidiabetic and anti-glycation activities&lt;/p&gt;
</article-title>
  <contrib-group><contrib><name><string>Abdul Samad Khan, Abdul Haleem Shah, Sadia Chaman, Sidra Altaf, Ayesha Haleem Shah, Muhammad Zafar and Adnan Amin</string></name></contrib></contrib-group>
  <abstract>&lt;p style=&quot;text-align: justify;&quot;&gt;
	Traditional medicinal plant&lt;em&gt; Valeriana wallichii&lt;/em&gt; is comprised of diverse medicinal phytochemicals with a broad range of bioactivities. This investigation comprehensively evaluates antidiabetic and antiglycation activities of &lt;em&gt;V. wallichii. &lt;/em&gt;An integrated analytical-computational and &lt;em&gt;In vitro&lt;/em&gt; approach was used, comprising LC&amp;ndash;MS Qtof analysis, &lt;em&gt;In silico &lt;/em&gt;ADME profiling and docking analysis and antioxidant, antidiabetic and AGEs inhibitory assays.&amp;nbsp; Phytochemical profiling identified multiple compounds, like phenolics, flavonoids, phenolics and terpenoids. Significant activity antioxidant potential was shown by ethyl acetate part (H₂O₂ scavenging: 81.2%, DPPH IC₅₀ 0.091 mg/mL), &amp;alpha;-glucosidase inhibition (IC₅₀ 0.13 mg/mL) and antiglycation effects, including decreased fructosamine levels (~0.48 mM/mL), higher carbonyl trapping (~23 &amp;mu;M/mg), and inhibition of &amp;beta;-amyloid formation. Further, a marked protection against groups was also noticed in the case of the ethyl acetate fraction. Favorable drug likeness and ADMET profiles were noticed during &lt;em&gt;In silico &lt;/em&gt;analysis with valerianic acid and Valeriandoid F showing strong binding affinities (up to &amp;minus;7.3 kJ&amp;middot;mol⁻&amp;sup1;) against key protein targets including 3CJJ, 3TOP and 4F5S. These interactions were stabilized by hydrogen bonding and hydrophobic bonds. It was thus evident that &lt;em&gt;V. wallichii&lt;/em&gt;, especially its semi-polar fraction, can modulate oxidative stress, carbonyl formation, and protein glycation pathways related to diabetic complications. Further &lt;em&gt;In vivo&lt;/em&gt; validation is required to confirm its clinical applicability.&lt;/p&gt;
</abstract>
  <publication-status>inpress</publication-status>
  <year>2027</year>
  <volume>59</volume>
  <issue>3</issue>
  <pages-from>1</pages-from>
  <pages-to>16</pages-to>
</article>
